President & CEO
Nick joined Aastrom in 2013 with more than twenty years of executive management and corporate development experience in the biopharmaceutical industry, including nearly a decade with Eli Lilly and Company. Most recently, Nick was President and Chief Executive Officer of Promedior, Inc. During his career, he has held a variety of executive positions of increasing responsibility in product development, pharmaceutical operations, sales and marketing, and corporate development. He has extensive experience in the acquisition, development and commercialization of therapies to treat fibrovascular, metabolic and cardiovascular diseases. During his tenure at Eli Lilly and Company, Nick held positions as Director of Strategy and Business Development for Lilly’s Diabetes Product Group and also served as a founding Managing Director of Lilly Ventures. Nick received his B.S.B.A. in Accounting, Magna Cum Laude, from the State University of New York at Buffalo and a J.D. degree, with Honors, from the Duke University School of Law.
Chief Operating Officer
Dan joined Aastrom in August of 2012 and is responsible for commercialization strategies and business development. He has more than 20 years of commercial product preparation and launch experience including leadership roles in sales, marketing and most recently as a vice president of business development for North and South America at Takeda Pharmaceuticals. As an early employee at Takeda North America, he served as the original brand director for Actos, which became the #1 branded anti-diabetic agent in the U.S. Dan’s initial pharmaceutical experience came in progressively expanding roles in sales and marketing at Abbott Laboratories. Dan holds an MBA from Florida Atlantic University and a BA in Economics with Honors from the University of Florida.
David Recker, MD
Chief Medical Officer
David Recker has more than 20 years of experience in drug development most recently at Takeda Global Research and Development where he served as Senior Vice President for Clinical Science. Dr. Recker has had responsibility for multiple development programs in a variety of therapeutic areas in his career which have resulted in many successful regulatory filings throughout the world. He is a Fellow of the American College of Physicians as well as a Fellow of the American College of Rheumatology. He holds an M.D. with Distinction form the University of Michigan where he did his internship and residency and was Chief Resident in Internal Medicine. He did his fellowship in training at the National Institutes of Health.
Chief Financial Officer & Vice President of Corporate Development
Gerard joined Aastrom in June of 2014 with over 25 years of experience in the pharmaceutical industry across multiple functional areas. He has considerable experience in business development, raising capital and executing successful financial transactions, raising over $500M in his career. Mr. Michel was formerly chief financial officer and vice president, corporate development of Biodel, where he oversaw strategic development, fundraising and capital structure management, marketing efforts, investor relations, and financial reporting and internal controls. Prior to his role at Biodel, Mr. Michel served as chief financial officer and vice president of corporate development of NPS Pharmaceuticals, where he led the first syndicated royalty monetization, the structure of which has been widely copied. Prior to that, Mr. Michel was a Principal at Booz Allen and also held a variety of commercial roles at both Lederle Labs and Wyeth Labs. Gerard holds a MS in Microbiology from the University of Rochester School of Medicine, an MBA from the Simon School of Business, and a BS in both Biology and Geology from the University of Rochester.
Ross Tubo, PhD
Chief Scientific Officer
Ross joined Aastrom in April 2014 with more than twenty years of experience in cell therapy, regenerative medicine, and stem cell biology. Dr. Tubo was a pioneer in the research, development, and commercialization of the first autologous cell therapy for articular cartilage repair, known as Carticel. As Vice President of Stem Cell and Chemokine Biology for Genzyme Corporation, he developed a world-class research organization designed to understand the underlying cell and molecular mechanism(s) of action of mesenchymal stem cells (MSCs) in autoimmune disease and cancer. These efforts led to the identification of specific therapeutic targets for treatment of these diseases. He holds a Ph.D. in Cell and Molecular Biology from State University of New York at Buffalo and completed post-doctoral studies at Harvard Medical School.